Boehringer Ingelheim
pradaxa_banner_hero

Pradaxa 

Prevent the stroke

Did you know? For decades vitamin K antagonists remained the gold standard for stroke prevention in AF, thanks to their high efficacy.1

Pradaxa® 150mg was also the first and only non-vitamin K anticoagulant that has proved a relative risk reduction versus warfarin for ischemic or unspecified strokes by 24%*[2-4]

Please take a look at further findings from the landmark study of Pradaxa®, RE-LY®, that changed the approach to stroke prevention in
AF[2-5]:

Have you ever considered the effectiveness of anticoagulation in patients with type 2 diabetes (T2D)?

In 2017 Anna Plitt post-hoc RE-LY® analysis Pradaxa® 150mg among all NOACs has demonstrated superiority versus warfarin in both group of patients with, or without T2D[6]:

effective stroke prevention
Footnotes

* 1.34% per year in the 110mg dabigatran group, 0.92% per year in the 150mg dabigatran and 1.21% per year in the warfarin group (relative risk for 150mg vs warfarin 0.76; 95% CI, 0.59 to 0.97 P=0.03)

References
  • 1.
    Hart RG et al Ann Intern Med 2007 Jun 19;146(12):857-67.
  • 2.
    Connolly SJ et al N Engl J Med 2009 Sep 17;361(12):1139-51.
  • 3.
    Connolly SJ et al N Engl J Med 2010 Nov 4;363(19):1875-6.
  • 4.
    Connolly SJ et al N Engl J Med 2014;371:1464-1465.
  • 5.
    Hindricks G et al Eur Heart J 2021 Feb 1;42(5):373-498.
  • 6.
    Plitt A et al JAMA Cardiol. 2017 Apr 1;2(4):442-448.

Graphic ‘Dabigatran vs. warfarin‘ adapted from Connolly et al. 20092, Connolly et al. 20103, Connolly et al. 2014[4]

Graphic ‘RE-LY’ adapted from Plitt et al. 2017[6]